Augmenix Revenue and Competitors

Claim your profile

Boston, MA USA



Total Funding

Estimated Revenue & Valuation

  • Augmenix's estimated annual revenue is currently $47.4M per year.(i)
  • Augmenix's estimated revenue per employee is $251,000

Employee Data

  • Augmenix has 189 Employees.(i)
  • Augmenix grew their employee count by 3% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation

Augmenix, Inc. is a privately held medical device company focused on the development and commercialization of radiation oncology and urology products using its proprietary hydrogel technology. The company is using this technology to develop products that decrease unintended radiation damage to normal organs during cancer radiation therapy and to mark soft tissue. The SpaceOAR System (OAR stands for organ at risk) is an absorbable hydrogel that temporarily moves the rectum away from the prostate and the high intensity radiation zone, protecting the rectum in men undergoing radiation therapy for prostate cancer. Clinically proven, the created space reduces rectal radiation injury and the resulting long term complications. It is the first and only prostate cancer spacing device to receive Food and Drug Administration (FDA) clearance. Additionally, Augmenix has developed an absorbable tissue marker that marks soft tissue for a surgical procedure or future surgical procedures. TraceIT Tissue Marker is visible on multi-modality imaging allowing for improved tissue marking. This technology, licensed from Incept, LLC, comes from a line of products that have made a meaningful impact in the areas of neurosurgery and interventional cardiology. Augmenix is bringing this technology to the field of radiation oncology through high quality investors and an experienced management team. Augmenix, SpaceOAR, and SpaceOAR logo are registered trademarks of Augmenix, Inc.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Augmenix News

2017-11-07 - Augmenix® Announces Medicare Reimbursement Rates for the new CPT Code 55874, which will be used to bill SpaceOAR® Hydrogel, Effective January 2018

First and only prostate cancer spacing device available for use in the U.S. clinically proven to preserve patient quality of life following radiation therapy BEDFORD, Mass.–(BUSINESS WIRE)–November 7, 2017– Augmenix, Inc., a medical technology company that develops, manufactures and sells prop ...

2017-12-28 - Augmenix to Present at the 36th Annual J.P. Morgan Healthcare Conference

BEDFORD, Mass.–(BUSINESS WIRE)–December 28, 2017– Augmenix, Inc. a medical technology company that develops, manufactures, and sells proprietary absorbable hydrogels that separate and protect organs at risk during prostate radiotherapy, today announced that it will present at the 36th Annual J. ...

2018-05-14 - Augmenix, Inc. Announces Exciting Plans for the 2018 American Urological Association Meeting in San Francisco

BEDFORD, Mass.–(BUSINESS WIRE)–May 14, 2018– Augmenix, Inc. is pleased to announce that they will be exhibiting at this year’s American Urological Association meeting in San Francisco, California. Located at Booth 6251 Hall D, the company will be featuring their leading product, SpaceOAR® hydro ...

09/03/2019 - Boston Scientific closes $600m Augmenix buyout

Boston Scientific closes $600m Augmenix buyout ... based Augmenix, announced in September, called for $500 million in up-front cash and ...

09/07/2018 - Boston Scientific puts up $600m for Augmenix

Boston Scientific (NYSE:BSX) said yesterday that it put $600 million on the table for Augmenix and its SpaceOar device. The deal for Bedford, ...

09/03/2019 - Boston Sci closes on $4.3 billion deal for British health ...

Boston Scientific Corp., a medical device company with major operations in the Twin Cities, closed on a $4.3 billion acquisition of British health ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding